IHH Healthcare Issues 1.8 Million Shares Under Incentive Scheme

IHH Healthcare issued 1.8 million shares under an incentive scheme. The Malaysia-based integrated healthcare provider operates in Singapore, Malaysia, India, China, Turkey, and Europe/Southeast Asia through brands such as Acibadem, Mount Elizabeth, and Pantai. The company offers comprehensive care from primary to quaternary levels, as well as ancillary services like lab tests, imaging, and rehabilitation. Its services include day-to-day healthcare, specialist consultations, and local surgeries.

Malaysia-based integrated healthcare provider IHH Healthcare Berhad has announced a significant share issuance under its Enterprise Option Scheme (EOS). On 21 May 2025, the company detailed a series of corporate proposals involving the issuance of shares, with a total of 1,800,000 shares issued as a result of options exercised from various EOS grants spanning from 2016 to 2023 [1].

The breakdown of the share issuance includes:
- 11,000 shares issued at MYR 6.5500 for the 2016 grant
- 80,000 shares issued at MYR 6.0200 for the 2018 grant
- 71,000 shares issued at MYR 5.7900 for the 2019 grant
- 140,000 shares issued at MYR 5.9200 for the 2022 grant
- 178,000 shares issued at MYR 5.8700 for the 2023 grant

The latest issued share capital stands at MYR 20,107,767,251.820, with a total of 8,822,484,463 units. The listing date for these shares is set for 22 May 2025 [1].

This strategic move is part of IHH's ongoing efforts to enhance its capital structure and provide incentives to its employees through the EOS. The company aims to remain competitive in the healthcare sector by leveraging its extensive network of brands, including Acibadem, Mount Elizabeth, and Pantai, which operate in Singapore, Malaysia, India, China, Turkey, and Europe/Southeast Asia [1].

The recent share issuance follows a series of insider transactions, including acquisitions and disposals by the Employees Provident Fund Board, a substantial shareholder. These transactions highlight the active participation of key stakeholders in the company's capital management [1].

References:
[1] https://boston2.i3investor.com/web/announcement/detail/1962165